Hypocalcemia News and Research

RSS
FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prostate cancer

FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prostate cancer

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Amgen's XGEVA delays onset of bone metastases in men with prostate cancer

Amgen's XGEVA delays onset of bone metastases in men with prostate cancer

Positive top-line results from NPSP558 Phase 3 study on hypoparathyroidism

Positive top-line results from NPSP558 Phase 3 study on hypoparathyroidism

NPS announces new data from GATTEX Phase 3 study on short bowel syndrome

NPS announces new data from GATTEX Phase 3 study on short bowel syndrome

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Amgen's Prolia receives FDA approval for new indications to treat cancer patients

Amgen's Prolia receives FDA approval for new indications to treat cancer patients

NPS announces data about hypoparathyroidism to be presented at ASBMR 2011 meeting

NPS announces data about hypoparathyroidism to be presented at ASBMR 2011 meeting

Amgen to present data from several Prolia studies at ASBMR 2011 meeting

Amgen to present data from several Prolia studies at ASBMR 2011 meeting

GSK, NPS enter agreement to evaluate ronacaleret in new indications

GSK, NPS enter agreement to evaluate ronacaleret in new indications

EC grants marketing authorization for Amgen's XGEVA to prevent skeletal-related events

EC grants marketing authorization for Amgen's XGEVA to prevent skeletal-related events

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

AstraZeneca announces U.S. availability of vandetanib for rare medullary thyroid cancer

AstraZeneca announces U.S. availability of vandetanib for rare medullary thyroid cancer

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

State court jury rules in favor of Merck in FOSAMAX trial

State court jury rules in favor of Merck in FOSAMAX trial